prevalence makes earlier setting market more attractive and bigger for newer options than the late stage if they succeed .
For drugs targeting through androgen pathway - Now trials and clinical development is underway for second and third generation androgen receptor inhibitors ( ARN-509 , ODM-201 , ODM-204 , EPI-506 , VT-464 , TAS-3681 and DR103 ). While androgen synthesis inhibitors still needs a proof of concept in clinic due to failure of TAK-700 & TOK-001 . Expected data from VT-464 ( Apr 2017 ) & ASN-001 will be important to watch to taste the success for this class . Androgen receptor degrader is another MoA in development from a decade and success of in clinic compound GTX-758 ( Data expected anytime from now as study completed in March 2016- less likely to succeed ) will decide the proof of concept .
For Sample Copy , click here : https :// marketreportscenter . com / request-sample / 505877
Other than pipeline drugs targeting androgen pathway , NCE targeting AKT pathway ( AZD5363 , Ipatasertib ) appears to be more promising to succeed in late stage , while drugs acting through PARP inhibition ( Olaparib , Niraparib ) still needs a taste of success . Other interesting pipeline asset is LHRH agonist LMIS 50 mg , which is designed to overcome the drawbacks of the commercial depot products containing GnRH agonists by using a proprietary delivery system .
Also 6 therapeutic vaccines are in clinical development to treat prostate cancer . Recently launched PD-L1 IO therapy has increased hope of treating cancer in much safer way . Current ongoing studies of late stage IO mab are in Ph I / II clinical development and would be able to answer of PTEN hypothesis for role of PD-1 , PD-L1 inhibitor to treat prostate cancer in coming years .
Resistant development is another challenge with long term use of Xtandi / Zytiga and needs to be addressed by pipeline second / third generation Antiandrogens / combination approach with IO / PARP / AKT inhibitors to treat mCRPC . Increase in pricing pressure in developed market again put inference on Combination approach unless the advantage is significant and improve the Q0L in earlier setting . Due to that , drugs targeting adjuvant setting has high bar to deliver ( Atezolizumab , GX301 , Mipsagargin and Olaparib ) in the clinical development to add significant value .
1 . This report details current unmet need , changing regulatory requirement , reimbursement challenges & market dynamics of Prostate Cancer drugs . Report mention pipeline Antiandrogens , late stage prostate cancer pipeline drugs / new Mechanism of action & major companies developing Prostate cancer drugs . It also provides insight on clinical development strategy of combination pipeline / marketed drugs & therapeutic competitive landscape to find treatment paradigm fit & market potential of new drugs for treatment of Prostate Cancer .